Trem2 (Triggering Receptor Expressed On Myeloid Cells 2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a transmembrane receptor of the immunoglobulin superfamily expressed primarily on [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--, releasing soluble TREM2 (sTREM2) into the extracellular space and cerebrospinal fluid[5]:
- CSF sTREM2 as a biomarker: sTREM2 levels in CSF are elevated in AD, peaking during the early symptomatic phase (MCI to mild dementia transition). sTREM2 tracks microglial activation independently of amyloid and tau] burden.
- Bioactive sTREM2: sTREM2 itself is bioactive — it promotes microglial survival through PI3K/Akt signaling and enhances inflammatory cytokine production[6].
- H157Y variant: The AD-associated H157Y variant occurs at the cleavage site and increases ADAM10-mediated shedding, elevating sTREM2 while reducing surface TREM2 signaling. This variant provides genetic evidence that the balance between surface TREM2 and sTREM2 is functionally important.
- Prognostic value: Higher baseline CSF sTREM2 is associated with slower cognitive decline in AD, suggesting that robust microglial activation (as reflected by sTREM2) is protective[7].
¶ Expression and Cellular Localization
In the brain, TREM2 is expressed almost exclusively on [microglia, the tissue-resident macrophages of the CNS:
- Expression is relatively low in homeostatic [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--, phosphatidylethanolamine, phosphatidylcholine, sphingomyelin, sulfatides
- Lipoproteins: ApoE (all three isoforms — ε2, ε3, ε4, with variable affinity), ApoJ/clusterin, LDL, HDL, lipoprotein-associated phospholipids
- Damage-associated molecular patterns: [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers and fibrils, myelin debris, neuronal debris, extracellular DNA
- Bacterial products: Lipopolysaccharide, lipoteichoic acid (relevant for neuroinfection contexts)
Upon ligand binding, the TREM2-DAP12 complex initiates a signaling cascade:
- TREM2 engagement induces conformational changes in DAP12, exposing ITAM tyrosines for phosphorylation by Src family kinases (Fyn, Lyn).
- Phosphorylated ITAMs recruit and activate Syk kinase, the central signaling hub.
- Syk activates multiple parallel downstream pathways:
| Pathway |
Key Mediators |
Functional Output |
| PI3K/Akt |
PI3Kγ, Akt, GSK3β |
Cell survival, anti-apoptosis, metabolic reprogramming |
| PLCγ/Ca2+ |
PLCγ2, IP3, DAG, Ca2+ |
Cytoskeletal rearrangement, phagocytosis, NFAT activation |
| [mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- |
mTORC1, S6K, 4E-BP1 |
Metabolic switching (glycolysis), translation, autophagy regulation |
| Wnt/β-catenin |
β-catenin, TCF/LEF |
Microglial proliferation and survival |
| ERK/MAPK |
Ras, Raf, MEK, ERK1/2 |
Gene expression, proliferation, chemotaxis |
TREM2 is essential for efficient microglial phagocytosis of:
- [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- fibrils and plaques — TREM2 mediates the "eat-me" signal recognition of [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---associated lipids
- Apoptotic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and cellular debris — TREM2 recognizes exposed phosphatidylserine
- Damaged myelin — critical for remyelination in white matter disease
- Synaptic material — TREM2-dependent synaptic pruning during development and disease
TREM2-deficient [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- and TREM2
TREM2 is the critical "checkpoint" regulator of the transition from homeostatic to disease-associated [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--**: Initial response to damage signals. Characterized by downregulation of homeostatic genes (P2ry12, Tmem119, Cx3cr1, Siglec-H) and upregulation of Tyrobp (DAP12), Apoe, B2m, and Cstb. This stage represents a "primed" state that occurs in response to initial tissue damage.
- Stage 2 (TREM2-dependent): Full DAM activation requiring functional TREM2 signaling. Characterized by upregulation of Lpl (lipoprotein lipase), Cst7, Cd9, Spp1 (osteopontin), Itgax (CD11c), Axl, Clec7a, and Gpnmb. TREM2-deficient mice are arrested at Stage 1 and cannot progress to Stage 2, confirming TREM2 as the obligate switch for full DAM activation.
Fully activated Stage 2 DAM exhibit:
- Enhanced phagocytic capacity: Increased uptake of amyloid fibrils, apoptotic cells, and myelin debris
- Lipid metabolism reprogramming: Upregulation of lipoprotein lipase (Lpl) and lipid transport genes enables processing of myelin-derived lipids and cholesterol
- Barrier function: DAM form a tight barrier around amyloid plaques, compacting diffuse amyloid into dense-core plaques and limiting the halo of neurotoxic oligomeric [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and dystrophic neurites
- Altered cytokine profile: Shift from homeostatic surveillance cytokines to a mix of pro-resolution and inflammatory mediators
- Morphological changes: Enlarged cell body (amoeboid morphology), retracted and thickened processes, increased surface area in contact with plaques
Single-cell and spatial transcriptomic studies have revealed microglial states beyond the original DAM classification:
- Lipid-droplet-accumulating [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--: Found in aging white matter; share some transcriptional features with DAM but are induced by myelin rather than amyloid.
TREM2 variants are the second strongest genetic risk factor for AD after [APOE[2]:
| Variant |
Allele Frequency |
Risk (OR) |
Mechanism |
| R47H |
~0.3% |
2.0–4.5x |
Impairs lipid/Aβ binding; reduces phagocytosis |
| R62H |
~1.5% |
1.4–1.7x |
Partially impairs signaling; more common |
| D87N |
Rare |
~3x |
Disrupts ligand binding surface |
| T96K |
Rare |
~2–3x |
Alters electrostatic interactions |
| H157Y |
~0.3% |
~1.5–2x |
Increases ectodomain shedding (cleavage site) |
Protective effects of TREM2: TREM2-mediated plaque compaction is protective in early disease. [Microglia
Temporal dynamics: Recent evidence suggests a critical therapeutic window for TREM2 activation. TREM2-dependent microglial responses are most protective during early amyloid deposition (Braak amyloid stages A–B), with diminishing returns or potentially adverse effects in advanced disease when tau] pathology is established. This timing-dependence is a key consideration for therapeutic development[4].
TREM2 variants are associated with Frontotemporal Dementia-like syndromes:
- Homozygous loss-of-function mutations (T66M, Y38C, Q33X) cause FTD as part of Nasu-Hakola disease
- Heterozygous variants (R47H, R62H) may modify tau] pathology in tauopathies
- TREM2 regulates microglial responses to [Tau[/proteins/[tau-protein[/proteins/[tau-protein[/proteins/[tau-protein[/proteins/[tau-protein--TEMP--/proteins)--FIX-- aggregation, with TREM2 deficiency reducing tau-driven neuroinflammation but potentially impairing debris clearance
¶ Parkinson's Disease and Lewy Body Dementia
TREM2 variants have been implicated in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- and [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--:
- R47H variant shows modest association with PD risk in some cohorts
- TREM2+ [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/alpha-synuclein/proteins/alpha-synuclein) aggregates in Lewy body disease
- Microglial phagocytosis of [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- is partially TREM2-dependent
TREM2 R47H has been investigated in [ALS[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- cohorts:
- Modest increased risk in some populations, though results are inconsistent across studies
- Altered microglial activation around [motor neurons[/cell-types/[motor-neurons[/cell-types/[motor-neurons[/cell-types/[motor-neurons[/cell-types/[motor-neurons--TEMP--/cell-types)--FIX-- in ALS spinal cord
- TREM2 may modify the neuroinflammatory component of motor neuron degeneration[13]
TREM2 is critical for myelin debris clearance during demyelination and remyelination:
- TREM2-deficient mice show impaired myelin debris phagocytosis and delayed remyelination
- sTREM2 levels in CSF correlate with disease activity in MS
- TREM2 agonism is being explored as a remyelination-promoting strategy
AL002 is a humanized IgG1 monoclonal antibody that binds the stalk region of TREM2, promoting TREM2 clustering and DAP12-mediated signaling. The Phase 2 INVOKE-2 trial (NCT04592874) in early AD was the first major clinical test of the TREM2 activation hypothesis[4][14]:
- Design: Randomized, double-blind, placebo-controlled trial of intravenous AL002 in patients with early AD (confirmed by amyloid PET or CSF biomarkers). N=265. Treatment duration: 96 weeks.
- Primary endpoint: Change from baseline in CDR-SB (Clinical Dementia Rating Sum of Boxes).
- Results (reported 2024): AL002 did not meet its primary endpoint and failed on all secondary and exploratory endpoints. No significant improvement in amyloid PET, tau] PET, or fluid biomarkers was observed.
- Safety signals: Treatment-emergent brain MRI changes resembling ARIA (amyloid-related imaging abnormalities) were observed, with higher incidence and severity in homozygous *[APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX--
VG-3927 is the first oral, brain-penetrant small molecule TREM2 agonist to enter clinical development, representing a fundamentally different pharmacological approach[16][17]:
- Mechanism: VG-3927 binds membrane-bound TREM2 with high specificity over sTREM2. Engagement triggers receptor internalization, roughly halving surface TREM2 levels and preventing shedding. Consequently, sTREM2 drops (opposite to AL002's effect). This differential mechanism may engage distinct downstream signaling pathways.
- Phase 1 results (2025): The trial enrolled 115 participants (healthy volunteers, elderly, and AD patients):
- Favorable safety and tolerability across all cohorts with no serious adverse events
- At the 25 mg dose, achieved ~50% maximum CSF sTREM2 reduction, confirming CNS target engagement
- PK/PD data support 25 mg once-daily oral dosing for Phase 2
- Biomarker effects differed significantly from AL002: sTREM2 decreased (vs. increased with AL002), and sCSF1R effects diverged, suggesting mechanistically distinct TREM2 engagement
- Phase 2: Planned in AD patients at the 25 mg oral dose. The oral route and brain penetrance offer significant advantages over IV antibody delivery.
- AAV-TREM2: Viral vector delivery of functional TREM2 to augment microglial activation, particularly in TREM2 loss-of-function variant carriers. Preclinical studies show restoration of microglial function in TREM2 knockout mice.
- CRISPR-based correction: Gene editing to correct specific risk variants (R47H, T66M) in patient-derived [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--, VHB937 (prevent shedding), and VG-3927 (internalize/signal) may produce qualitatively different microglial responses. Not all forms of TREM2 engagement are equivalent.
- Species differences: Murine TREM2 biology does not fully recapitulate human TREM2 function. Mouse models lack key human microglial transcriptional programs, limiting translational prediction.
- Dual role of microglia: TREM2-enhanced [microglia[/entities/[microglia[/entities/[microglia[/entities/[microglia[/entities/[microglia--TEMP--/entities)--FIX-- activity may improve pathogenic protein clearance, but excessive activation can amplify inflammatory injury depending on disease stage.
CSF sTREM2 is a validated biomarker of microglial activation with increasing clinical utility:
- Temporal profile in AD: sTREM2 rises early in the AD continuum, peaking around the MCI/mild dementia transition, then plateauing or declining in advanced disease
- Independent of amyloid: sTREM2 correlates with tau] pathology markers (pTau181, pTau217) and neurodegeneration ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, total tau] more strongly than with amyloid
- Prognostic value: Higher baseline sTREM2 is associated with slower cognitive decline, suggesting that robust microglial activation is protective. This has implications for trial design — patients with low sTREM2 (insufficient microglial response) may benefit most from TREM2 agonism[7]
- Trial stratification: sTREM2 is being evaluated as a biomarker for patient selection and pharmacodynamic monitoring in TREM2-targeted clinical trials
Plasma sTREM2 is less well-validated than CSF sTREM2 but is being developed as a non-invasive screening biomarker:
- Plasma sTREM2 shows modest correlation with CSF levels
- Confounded by peripheral TREM2 expression on monocytes and macrophages
- Ultrasensitive immunoassay platforms (Simoa) enable reliable detection
- Longitudinal changes in plasma sTREM2 may track disease progression
Integration of sTREM2 with other biomarkers enhances diagnostic and prognostic accuracy:
- AT(N) framework: sTREM2 complements amyloid (A), [tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- (T), and neurodegeneration (N) biomarkers by adding an immune/inflammatory dimension
- Multivariate models: Combining sTREM2 with [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--, [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--, and [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- improves prediction of disease progression beyond any single biomarker
The study of Trem2 (Triggering Receptor Expressed On Myeloid Cells 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [/diseases/alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [/mechanisms/amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis--TEMP--/mechanisms)--FIX--
- [/mechanisms/tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology--TEMP--/mechanisms)--FIX--
- [/diseases/parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [/mechanisms/alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--
- ([APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX-- 2. Neurodegenerative Disease Research) - Comprehensive reviews on disease mechanisms
- Alzheimer's Association) - Disease information and current research
- NIH National Institute on Aging) - Research updates and clinical trials## Brain Atlas Resources
-
-
-
-
-
- [Microglia — Primary cell type expressing TREM2
-
- [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- — Disease where TREM2 variants confer risk
-
- neuroinflammation — Inflammatory processes modulated by TREM2
-
- DAP12/TYROBP — Signaling adaptor for TREM2
-
- [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- — [Amyloid] pathology influenced by TREM2 function
-
- [ALS[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- — Another neurodegenerative disease linked to TREM2 variants